Peptides Similar to VK2735

Peptides Related to VK2735#

VK2735 is one of several next-generation dual-receptor agonists in development for obesity. As a dual GLP-1/GIP agonist, it belongs to the same pharmacological class as tirzepatide but is distinguished by its parallel development in both subcutaneous and oral formulations. The following comparisons highlight key differences in mechanism, efficacy, and development status.

Tirzepatide (Mounjaro/Zepbound)#

Tirzepatide is the most direct comparator as the only approved dual GLP-1/GIP agonist:

The 14.7% weight loss at 13 weeks (Phase 2) is not directly comparable to tirzepatide's 20.9% at 72 weeks (Phase 3), as VK2735's shorter treatment period and lack of plateau suggest further weight loss potential.

Semaglutide (Wegovy/Ozempic)#

Semaglutide is the selective GLP-1 agonist benchmark:

• Mechanism: Semaglutide is GLP-1-selective; VK2735 adds GIP receptor activation
• Weight loss: Semaglutide achieves approximately 15-17% at 68 weeks; VK2735 achieved 14.7% at just 13 weeks
• Oral formulations: Both have oral versions, but VK2735 oral does not require fasting (semaglutide oral requires 30 minutes fasting)
• Approval: Semaglutide is well-established with extensive safety and CV outcomes data

CT-388 (Roche/Carmot)#

CT-388 is another dual GLP-1/GIP agonist in clinical development:

• CT-388 reported 22.5% weight loss in Phase 2 (longer duration than VK2735 Phase 2)
• CT-388 is described as a biased dual agonist
• VK2735 is further in development (Phase 3 vs Phase 2)

Retatrutide (Eli Lilly)#

Retatrutide adds glucagon receptor activation for a triple-agonist approach:

• Highest reported weight loss in clinical trials (~24.2% in Phase 2)
• Glucagon receptor activity provides hepatic benefits (fat oxidation, thermogenesis)
• VK2735 offers the advantage of an oral formulation option

Summary Comparison#

Comparison Context#

VK2735 belongs to the Metabolic category of research peptides. Comparing VK2735 with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to VK2735 in mechanism, indication, or therapeutic category:

VK2735 vs Tirzepatide#

Similarity: Very High - Both are dual GLP-1/GIP receptor agonists with once-weekly subcutaneous dosing and similar efficacy targets

Key Differences: Tirzepatide is a single peptide with known structure (GIP backbone, C20 fatty diacid). VK2735's structure is proprietary. Tirzepatide is FDA-approved; VK2735 is in Phase 3. VK2735 also has an oral formulation.

Advantages of Tirzepatide: Both SC and oral formulations in development, potentially faster onset of weight loss (14.7% at 13 weeks), no strict fasting for oral formulation

Disadvantages of Tirzepatide: Not yet approved (tirzepatide is approved as Mounjaro/Zepbound), only Phase 2 data published, no head-to-head comparison data, no CV outcomes

Researchers choosing between VK2735 and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.

VK2735 vs Semaglutide#

Similarity: High - Both target GLP-1 receptors; semaglutide is selective GLP-1 while VK2735 adds GIP receptor activation

Key Differences: Semaglutide is a selective GLP-1 agonist; VK2735 is a dual GLP-1/GIP agonist. Semaglutide is approved in SC (Wegovy) and oral (Rybelsus) formulations. VK2735 oral does not require fasting.

Advantages of Semaglutide: Dual GLP-1/GIP mechanism may provide greater weight loss, oral formulation without fasting requirements

Disadvantages of Semaglutide: Not approved (semaglutide has extensive Phase 3 and CV outcomes data), smaller evidence base, no long-term safety data

Researchers choosing between VK2735 and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.

VK2735 vs CT-388#

Similarity: High - Both are dual GLP-1/GIP agonists in clinical development for obesity

Key Differences: CT-388 (Roche/Carmot) is a biased dual agonist with different receptor selectivity. CT-388 is in Phase 2; VK2735 has entered Phase 3. CT-388 reported 22.5% weight loss in Phase 2.

Advantages of CT-388: More advanced development stage (Phase 3 vs Phase 2 for CT-388), dual formulation strategy (SC + oral)

Disadvantages of CT-388: CT-388 showed higher Phase 2 weight loss (22.5% vs 14.7%), though different trial designs limit direct comparison

Researchers choosing between VK2735 and CT-388 should consider the development stage, available evidence, and specific research objectives when making their selection.

VK2735 vs Retatrutide#

Similarity: Moderate - Both are next-generation multi-receptor obesity therapies, but retatrutide adds glucagon receptor activation

Key Differences: Retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptor); VK2735 is a dual agonist (GLP-1 + GIP). Retatrutide has shown higher peak weight loss (~24.2% in Phase 2) but targets different metabolic pathways.

Advantages of Retatrutide: Dual formulation (SC + oral), potentially simpler mechanism with fewer unknown risks

Disadvantages of Retatrutide: Lower peak weight loss in cross-trial comparison, no glucagon receptor activity for hepatic benefits, less advanced Phase 3 program

Researchers choosing between VK2735 and Retatrutide should consider the development stage, available evidence, and specific research objectives when making their selection.

VK2735 vs Survodutide#

Similarity: Moderate - Both are dual-receptor agonists in development for obesity, but target different receptor combinations

Key Differences: Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon agonist; VK2735 is a dual GLP-1/GIP agonist. Different second receptor targets (glucagon vs GIP) provide different metabolic profiles.

Advantages of Survodutide: GIP receptor activation may complement GLP-1 differently than glucagon, oral formulation in development

Disadvantages of Survodutide: Survodutide showed ~18.7% weight loss at 46 weeks; trial designs differ making comparison difficult

Researchers choosing between VK2735 and Survodutide should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• VK2735 overview and research guide
• VK2735 research evidence
• VK2735 dosing protocols